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Background
Many variables contribute to the way we age and the con-
sequent possible achievement of extreme ages. Among
these, we can include cultural, anthropological and
socio-economic status as well as sex and gender (women
live longer than men). Also, ethnic differences (explained
by discrepancies in healthcare, environmental and eco-
nomic status, genetics as well as life occupation) exist in
relation to ageing/longevity. In any case, the concrete pos-
sibility to manifest a longevity phenotype is strictly related
to the stochastic interactions due to accidental events,
with environmental and genetic factors having a role in
ageing and longevity processes. The genetic component is
progressively a major determinant as we evaluate extreme
ages to be reached. Indeed, the possibility to inherit lon-
gevity increases with age: for long living individuals (LLIs),
which are people that belong to the top 5th percentile of
life-spans (i.e. 95 years in males and 98 years in female), it
reaches up to 33% for women and 48% for men [1–3]
(https://www.ssa.gov/OACT/STATS/, under “life table”).
Genetics of exceptional longevity has been developed
with different approaches depending on the available tech-
nologies and on the costs for a single analysis. Although
the reduced costs have allowed more comprehensive stud-
ies, more is not always better. As an example, given the
number of samples available for a given genetic analysis,
the power of the study is reduced progressively as we add
more hypothesises to test, to the point that the study be-
comes underpowered in genome-wide association studies
(GWAS) [4].
In other words, there is no simple equation, such as
more hypotheses =more results. Indeed, APOE ε4 allele
was associated with exceptional longevity in 1994 through
a candidate gene approach using a small sample size [5].
Since then, many replication attempts were successful,
despite the fact that there is a strong gradient in terms of
ε4 allele frequency among Northern and Southern
European studies (lower in the South) [6]. APOE was so
strongly associated that it came up in most GWAS for
exceptional longevity, surviving the Bonferroni’s correc-
tion of the threshold of significance adopted for GWAS
(p < 5 × 10− 8). This is also true for the FOXO3A locus,
while for others replication attempts were not consistent,
possibly due to the multiple testing that reduced the
threshold of significance [7, 8]. Thus, in the era of candi-
date gene studies in exceptional longevity, the limitation
was not underpowered studies, but the lack of correction
for genetic admixture. Indeed, stratification, which is the
bias that brings to an enrichment of a specific ethnicity in
one of the two arms (cases and controls) of the study, is
the main cause of false positive results [4].
In an attempt to reconcile the results of different stud-
ies, statistics that included different studies (meta-analysis)
was developed. Still, the non-homogeneous criteria
adopted to select the two arms of a case-control study
could result in conflicting results. Among the criteria that
vary among the studies, it is important to mention the
ages of LLIs and the young controls and gender distribu-
tion, parameters that could influence associations of gen-
etic variants that intervene at extreme ages and with a
gender effect [9].
Recently, many studies have been accomplished using
chip arrays that interrogated hundreds of thousands of
single nucleotide polymorphisms (SNPs,) followed by
the imputation of the missing SNPs allowing a compre-
hensive analysis of the entire genome, with some excep-
tions where polymorphisms were not well represented at
the chip level. Furthermore, the Bonferroni’s correction
is a strong killer for genetic risk factors with small ef-
fects unless the number of individuals tested is in the
* Correspondence: calogero.caruso@unipa.it
1Department of Pathobiology and Medical Biotechnologies, Section of General
Pathology, University of Palermo, Corso Tukory 211, 90134 Palermo, Italy
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Caruso et al. Immunity & Ageing           (2018) 15:25 
https://doi.org/10.1186/s12979-018-0133-8
tens of thousands. The LLIs are healthy individuals that
are not hospitalized and are recruited by home visiting,
making it difficult to reach large numbers [4].
Discussion
Candidate gene studies involving the genomic regions
that are not well represented in the SNP arrays are
therefore welcome for the discovery of new potential as-
sociations with exceptional longevity. It is useful to
adopt populations that have already been used for
GWAS so as to exclude stratification effects. This is in-
deed the case for the study presented by Puca et al., [10]
which analysed the role of genetic markers of γ chains
(GM allotypes), i.e. the hereditary antigenic determinants
expressed on immunoglobulin G polypeptide chains, in
the attainment of longevity. In this study, the DNA sam-
ples from 95 LLIs (mean age 96.7) and 96 young con-
trols (mean age 31.9) from South Italy were typed for
GM3/17 and GM23+/− alleles, showing that GM3 allo-
type is significantly overrepresented in both male and fe-
male LLIs. The rs1071803 SNP that codes for the GM 3/
17 (arginine/lysine) allotypes is not represented in the
commonly employed genotyping platforms. It can be im-
puted, but the quality of imputation is poor.
Literature data show that human longevity may be cor-
related with optimal functioning of the immune system,
so suggesting that genetic determinants of longevity also
resides in those polymorphisms for the immune system
genes that regulate immune responses, such as human
leukocyte antigen (HLA) [11, 12]. Accordingly, several
studies have examined the role of HLA antigens in lon-
gevity [11, 13]. It has been known since at least 1971 [14]
that GM allotypes contribute to the interindividual differ-
ences in the magnitude of immune responsiveness, so it is
not surprising that GM allotypes are seemingly associated
with longevity, it is instead surprising that until now no
study was performed on GM allotypes and longevity.
As first suggested by J.B.S. Haldane [15], major infec-
tious diseases have been the principal selective forces in
shaping our evolutionary history. GM allotypes have been
shown to be associated with immune responsiveness to
several major infectious pathogens and with survival from
epidemics [16]. One mechanism for how GM determi-
nants could contribute to the outcome of infection with
various agents may be through allotype-mediated antibody
responses against pathogens, resulting in differential
immunity to infectious diseases. Thus, GM allotypes could
participate as recognition structures for the pathogenic
epitopes on B cell membranes. Additionally, and contrary
to the prevalent belief in immunology, these constant-re-
gion determinants could directly influence antibody
specificity by causing conformational changes in the
antigen-binding site in the immunoglobulin variable
region. They could also influence the expression of
idiotypes involved in immunity to the pathogens. Contri-
bution of both variable and constant regions in the forma-
tion of idiotypic determinants was documented many
years ago [17].
Conclusion
Human population is very heterogeneous because of the
different genetic background and different environmen-
tal stimuli, so it has not yet been possible to identify a
clear signature of longevity with the exception of APOE
and FOXOA. The study of Puca et al., [10] was per-
formed in a very homogeneous population from South
Italy, so the observed association of GM with longevity
should not depend on population stratification. How-
ever, further studies are necessary to confirm this associ-
ation. GM17/17 (the alternative allele of GM3) has been
shown to be associated with the risk of developing
HCMV symptomatic infection [18]. Considering the role
of HCMV in immunosenescence [19, 20], future studies
might evaluate antibodies titers directed versus HCMV
in LLIs and young controls, according to GM3 allotype.
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